Bioavailability Enhancement - Oral Drug Products and Intermediates

Bioavailability Enhancement - Oral Drug Products and Intermediates
Product Description

The depth of our bioavailability (BA) enhancement offering makes us a leader in addressing addressing low solubility, low bioavailability and dissolution rate issues. We work collaboratively with our customers to advance compounds, or re-purpose existing compounds, across a full range of API properties and delivery challenges. Our end-to-end solutions incorporate full capabilities in bringing a compound from concept to commercialization, thereby minimizing program complexity, timelines and risk.

Industry estimates indicate that more than 80% of new chemical entities exhibit low solubility, low bioavailability and / or low or inconsistent dissolution rate. Effectively addressing these drug solubility, bioavailability and dissolution rate problems is essential for advancing the compound and providing the desired therapeutic benefit of the drug product to patient. And ensuring that the solubility solution incorporates the ultimate manufacturability of the drug product can avoid time-consuming re-formulation and rapid advancement to market.

We recognize the core challenges of advancing the new chemical compounds in today’s biopharmaceutical pipeline. That’s why we have developed a portfolio of bioavailability enhancement technologies and services with which to address poor solubility and inadequate or inconsistent dissolution rate.

Our commitment to our customers includes a 20+ year track record across our bioavailability enhancement approaches with phase-appropriate processing in place to support non-GMP feasibility assessments through GMP clinical trials and commercial-scale manufacturing.
Proven bioavailability enhancement technologiesOur bioavailability enhancement technologies include:

Particle size reduction: micronization and nano-millingSolid dispersion technologies: hot-melt extrusion or spray dryingSpecialized nanocrystalline dispersion and spray-dried nanoadsorbate technologiesComplementary drug delivery technologies are utilized to modulate pharmacokinetics of the solubilized compound and achieve a full range of absorption profiles.

Our scientists take a data-driven approach to characterizing BA problem statement(s) and selecting the enabling technology to advance your compound.

Our integrated product design and development services provide the full range of capabilities to support the rapid advancement of compounds from concept to clinic. This range of services has been integrated in our SimpliFiH® Solutions offering designed to be phase-appropriate and to simplify your pathway to IND/IMPD studies:

  • API development and supply
  • API characterization
  • Product design and preformulation development
  • Formulation and product development
  • Analytical services and quality control
  • Clinical trial manufacture
  • Clinical packaging and supply services
Additionally, our SimpliFiH® Solutions integrated service package is designed specifically to rapidly advance compounds to first-in-human studies.


Read more Show less

Lonza Capsules & Health Ingredients

  • CH
  • 2015
    On CPHI since
View company profile
Categories
more categories Show less

Lonza Capsules & Health Ingredients

  • CH
  • 2015
    On CPHI since
View company profile

More Products from Lonza Capsules & Health Ingredients (4)

  • Active Pharmaceutical Ingredients and Intermediates

    Product Active Pharmaceutical Ingredients and Intermediates

    We provide customized chemical synthesis for active pharmaceutical ingredients from concept to commercial supply.

    We are an industry-leading integrated development and manufacturing service provider for small molecule drug substances and their intermediates.

    Chemistry is c...
  • Highly Potent API Handling

    Product Highly Potent API Handling

    HPAPI product handling from concept to commercial-scale manufacturing 

    Utilizing a combination of technology, infrastructure and expertise, we provide you with seamless, flexible HPAPI development and manufacturing tailored to your specific needs and resulting in reduced program timelin...
  • Inhalation Formulation Services

    Product Inhalation Formulation Services

    Inhaled drug products for nasal or pulmonary delivery continue in popularity due to the prevalence of respiratory diseases around the globe. Additionally, the lung’s absorptive capacity continues to be explored as an attractive delivery point for both local and systemic applications. Particle engineering, ...
  • Microreaction Technology

    Product Microreaction Technology

    Use of Microreaction Technology (MRT) may lower product cost of goods and increases yield and throughput of a manufacturing facility. This technology is able to perform hazardous, high temperature and pressure reactions, as well as those containing unstable or extremely reactive elements. Using MRT, these ...

Lonza Capsules & Health Ingredients resources (6)

  • CPHI North America 2023 – From the Floor

    News CPHI North America 2023 – From the Floor

    Follow along for live updates from the Content team as we bring you the latest from CPHI North America 2023 - from session talks, panel discussions, interviews, and more, there's a lot to discover with CPHI Online at the Pennsylvania Convention Center! 
    24 Apr 2023
  • Lonza

    Video Lonza

    Enabling a healthier world.
    2021-10-13
  • Lonza signs five-year collaboration deal with VC firm Bioqube to speed up portfolio companies’ development and manufacturing

    News Lonza signs five-year collaboration deal with VC firm Bioqube to speed up portfolio companies’ development and manufacturing

    The offering will accelerate timelines for the development and manufacturing of molecules and disruptive technologies
    30 Nov 2021
  • Making a Splash in the US Market: How PBPK Modeling is Playing a Central Role in Risk Reduction in Early Drug Development

    Video Making a Splash in the US Market: How PBPK Modeling is Playing a Central Role in Risk Reduction in Early Drug Development

    Rapid and efficient development of drug candidates is increasingly important for pharmaceutical companies with accelerated timelines and funding constraints. However, many early drug candidates have poor oral absorption properties making it challenging to achieve target pharmacokinetic (PK) profiles. Without upfront knowledge of absorption risks and mitigation strategies, poor absorption can significantly impact preclinical and clinical study timelines and costs. Physiologically-based pharmacokinetic (PBPK) modeling software, such as the GastroPlus® platform from Simulations Plus, simulates dynamic physiological factors impacting oral performance. When coupled with in vitro measurements, PBPK modeling is effective in early development for 1) identifying absorption risks, 2) assessing the potential for solubility enhancing formulations such as salts, cocrystals, or amorphous solid dispersions to mitigate these risks, and 3) designing and optimizing preclinical and clinical studies with respect to dose, prandial state, or gastric pH modification to maximize the likelihood of achieving desired PK profiles. In this presentation, we will demonstrate how PBPK models combined with Lonza’s custom and off-the shelf in vitro tools and solubility enhancement expertise can be used to identify and mitigate absorption risks in early drug development, reducing the need for drug product reformulation or repeated preclinical or clinical studies. Key Learning Objectives: Learn how PBPK modeling can identify potential oral absorption risks and mitigation strategies (e.g. bioavailability enhancement) for early drug candidates. Learn how PBPK modeling coupled with in vitro testing can guide early selection of drug form and formulation to achieve clinical study goals. Gain insights into how key drug and formulation factors including solubility, permeability, and dissolution rate can impact absorption risks such as poor oral bioavailability, food-drug interactions, and pH-dependent DDI effects.
    2023-05-09
  • Lonza Switzerland site to undergo expansion of microbial development capabilities

    News Lonza Switzerland site to undergo expansion of microbial development capabilities

    The expansion includes the installation of a pilot suite with a 50-L fermenter and automation upgrades to accelerate clinical and commercial projects
    17 Nov 2021
  • Lonza boosts exosome capability with Codiak BioSciences facility acquisition

    News Lonza boosts exosome capability with Codiak BioSciences facility acquisition

    The companies will establish a Centre of Excellence focused on exosome manufacturing and characterization technologies
    3 Nov 2021